Literature DB >> 21849452

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Georgia D Tomaras1, James M Binley, Elin S Gray, Emma T Crooks, Keiko Osawa, Penny L Moore, Nancy Tumba, Tommy Tong, Xiaoying Shen, Nicole L Yates, Julie Decker, Constantinos Kurt Wibmer, Feng Gao, S Munir Alam, Philippa Easterbrook, Salim Abdool Karim, Gift Kamanga, John A Crump, Myron Cohen, George M Shaw, John R Mascola, Barton F Haynes, David C Montefiori, Lynn Morris.   

Abstract

A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of exceptional magnitude and breadth. A detailed analysis of the critical epitopes targeted by broadly neutralizing antibodies should help to define optimal targets for vaccine design. HIV-1-infected subjects with potent cross-reactive serum neutralizing antibodies were identified by assaying sera from 308 subjects against a multiclade panel of 12 "tier 2" viruses (4 each of subtypes A, B, and C). Various neutralizing epitope specificities were determined for the top 9 neutralizers, including clade A-, clade B-, clade C-, and clade A/C-infected donors, by using a comprehensive set of assays. In some subjects, neutralization breadth was mediated by two or more antibody specificities. Although antibodies to the gp41 membrane-proximal external region (MPER) were identified in some subjects, the subjects with the greatest neutralization breadth targeted gp120 epitopes, including the CD4 binding site, a glycan-containing quaternary epitope formed by the V2 and V3 loops, or an outer domain epitope containing a glycan at residue N332. The broadly reactive HIV-1 neutralization observed in some subjects is mediated by antibodies targeting several conserved regions on the HIV-1 envelope glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849452      PMCID: PMC3194956          DOI: 10.1128/JVI.05363-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  108 in total

1.  Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Authors:  Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

2.  Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.

Authors:  Avishek Nandi; Christine L Lavine; Pengcheng Wang; Inna Lipchina; Paul A Goepfert; George M Shaw; Georgia D Tomaras; David C Montefiori; Barton F Haynes; Philippa Easterbrook; James E Robinson; Joseph G Sodroski; Xinzhen Yang
Journal:  Virology       Date:  2009-11-17       Impact factor: 3.616

3.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

4.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

5.  Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Authors:  Elin S Gray; Natasha Taylor; Diane Wycuff; Penny L Moore; Georgia D Tomaras; Constantinos Kurt Wibmer; Adrian Puren; Allan DeCamp; Peter B Gilbert; Blake Wood; David C Montefiori; James M Binley; George M Shaw; Barton F Haynes; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

6.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

Authors:  Ann J Hessell; Pascal Poignard; Meredith Hunter; Lars Hangartner; David M Tehrani; Wim K Bleeker; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nat Med       Date:  2009-06-07       Impact factor: 53.440

7.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

8.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

9.  Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Authors:  Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

Review 10.  The immune response during acute HIV-1 infection: clues for vaccine development.

Authors:  Andrew J McMichael; Persephone Borrow; Georgia D Tomaras; Nilu Goonetilleke; Barton F Haynes
Journal:  Nat Rev Immunol       Date:  2009-12-11       Impact factor: 53.106

View more
  125 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Authors:  Mattia Bonsignori; David C Montefiori; Xueling Wu; Xi Chen; Kwan-Ki Hwang; Chun-Yen Tsao; Daniel M Kozink; Robert J Parks; Georgia D Tomaras; John A Crump; Saidi H Kapiga; Noel E Sam; Peter D Kwong; Thomas B Kepler; Hua-Xin Liao; John R Mascola; Barton F Haynes
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

4.  Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates.

Authors:  Lukas Flatz; Cheng Cheng; Lingshu Wang; Kathryn E Foulds; Sung-Youl Ko; Wing-Pui Kong; Rahul Roychoudhuri; Wei Shi; Saran Bao; John-Paul Todd; Mohammed Asmal; Ling Shen; Mitzi Donaldson; Stephen D Schmidt; Jason G D Gall; Daniel D Pinschewer; Norman L Letvin; Srinivas Rao; John R Mascola; Mario Roederer; Gary J Nabel
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 5.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

6.  Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors:  Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

7.  Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.

Authors:  Feng Gao; Mattia Bonsignori; Hua-Xin Liao; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Fangping Cai; Kwan-Ki Hwang; Hongshuo Song; Tongqing Zhou; Rebecca M Lynch; S Munir Alam; M Anthony Moody; Guido Ferrari; Mark Berrong; Garnett Kelsoe; George M Shaw; Beatrice H Hahn; David C Montefiori; Gift Kamanga; Myron S Cohen; Peter Hraber; Peter D Kwong; Bette T Korber; John R Mascola; Thomas B Kepler; Barton F Haynes
Journal:  Cell       Date:  2014-07-24       Impact factor: 41.582

8.  Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.

Authors:  Juan García-Arriaza; Beatriz Perdiguero; Jonathan Heeney; Michael Seaman; David C Montefiori; Celia Labranche; Nicole L Yates; Xiaoying Shen; Georgia D Tomaras; Guido Ferrari; Kathryn E Foulds; Adrian McDermott; Shing-Fen Kao; Mario Roederer; Natalie Hawkins; Steve Self; Jiansheng Yao; Patrick Farrell; Sanjay Phogat; Jim Tartaglia; Susan W Barnett; Brian Burke; Anthony Cristillo; Deborah Weiss; Carter Lee; Karen Kibler; Bert Jacobs; Benedikt Asbach; Ralf Wagner; Song Ding; Giuseppe Pantaleo; Mariano Esteban
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

Review 9.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

10.  Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.

Authors:  Joshua D Amos; Jonathon E Himes; Lawrence Armand; Thaddeus C Gurley; David R Martinez; Lisa Colvin; Krista Beck; R Glenn Overman; Hua-Xin Liao; M Anthony Moody; Sallie R Permar
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.